BioCryst Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 88   

Articles published

BCRX 8.30 +0.19 (2.34%)
price chart
Review on Stocks On The Dive - BioCryst Pharmaceuticals, Inc. (NASDAQ ...
On Monday, Following Stocks were among the �Top 100 Losers� of U.S. Stock Market: BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals VP Sells $122986.80 in Stock (BCRX)  sleekmoney
Closing Bell Reports: BioCryst Pharmaceuticals, Inc. (BCRX), Zillow Group ...  WallStreet Scope
Downward Momentum Stocks: BioCryst Pharmaceuticals, (NASDAQ:BCRX ...
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) decreased -2.66%, and closed at $8.78. The company holds the market capitalization of $652.33M.
Earnings Peek: BioCryst Pharmaceuticals Likely To Beat Estimates (BCRX)
BioCryst Pharmaceuticals (NASDAQ:BCRX) is a small biotechnology company with a market cap of $814 million. It develops novel small molecule drugs that block key enzymes involved in orphan and infectious diseases.
BioCryst Pharma (BCRX) Granted Orphan Drug and Fast Track Status from the ...  Wall Street Pit
FDA Grants Fast Track Designation for BCX4161 for the Treatment of ...  MarketWatch
BioCryst Pharmaceuticals, Inc. Insider Transaction Update: Yarlagadda Babu ...
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX),The Officer (Senior VP - Drug Discovery) of BioCryst Pharmaceuticals, Inc., Babu Yarlagadda S sold 37,400 shares at $10.59 on March 5, 2015. The Insider selling transaction had a total value worth of ...
Insider Selling: BioCryst Pharmaceuticals VP Yarlagadda S. Babu Sells 37400 ...  Dakota Financial News
Company Shares of BioCryst Pharmaceuticals, Inc. Drops by -1.52%  Winston View
Technical Insights on BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
[GLOBE NEWSWIRE] BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (TREND ANALYSIS) announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company's clinical programs at the following investor ...
Insider Selling: BioCryst Pharmaceuticals VP Sells 10495 Shares of Stock (BCRX)  sleekmoney
Insider Selling: BioCryst Pharmaceuticals VP Yarlagadda S. Babu Sells 10495 ...  Mideast Time
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) in Spotlight
[GLOBE NEWSWIRE] BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (TREND ANALYSIS) announced financial results for the fourth quarter and full year ended December 31, 2014.
Price Target Update on BioCryst Pharmaceuticals, Inc.  Bar and Graph Report
Revenue Update on BioCryst Pharmaceuticals, Inc.  Ashburn Daily
Why BioCryst Pharmaceuticals Inc. Shares Soared
What: Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX ) , a biotechnology company focused on developing small-molecule drugs designed to block enzymes which are vital to the disease development process, spiked higher by as much as 22% after ...
BioCryst Pharmaceuticals Prices Public Offering of Common Stock  GlobeNewswire (press release)
BioCryst Announces Positive Results From OPuS-1, a Phase 2 Trial of BCX4161 ...  MarketWatch
Related articles »  
Stock in Focus: BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
[GLOBE NEWSWIRE] BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (TREND ANALYSIS) announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company's development programs at ...
Analyst Rating Update on BioCryst Pharmaceuticals, Inc.
Analysts at Zacks have given a short term rating of hold on Biocryst Pharmaceuticals (NASDAQ:BCRX) with a rank of 3. The counter has received an average rating of 1.71 from 7 brokerage firms.
BioCryst Pharmaceuticals Short Interest Up 15.8% in February (BCRX)  WKRB News
Stock Insight: BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
[GLOBE NEWSWIRE] BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (TREND ANALYSIS) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for BCX4161, a novel, orally administered, selective inhibitor of ...